Shigellosis and enterotoxigenic Escherichia coli (ETEC)
Shigella and enterotoxigenic Escherichia coli (ETEC) are two of the leading bacterial causes of diarrhea worldwide, and, together, they account for about one billion cases of diarrhea annually. Insufficient data exist, but conservative estimates suggest that, combined, Shigella and ETEC are responsible for almost one-third of the nearly 600,000 child deaths from diarrhea each year, as well as many deaths in older age groups. Shigellosis and illness from ETEC usually follow the ingestion of contaminated food or water. Shigella can also be transferred by person-to-person contact. ETEC can usually be treated through rehydration therapy, and both Shigella and ETEC can be treated with antibiotics, although the rate of resistance to the most commonly used antibiotics is sharply on the rise for Shigella. Currently, no licensed vaccines targeting Shigella or ETEC exist; however, vaccines against both bacteria are in development.
Progress and Hurdles in the Development of Vaccines Against Enterotoxigenic Escherichia coli in Humans (2012)
An article that describes ETEC vaccine candidates under development.
The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease (2012)
An article that presents findings from a Phase 2b challenge study of a vaccine against ETEC.
Featured PATH resources
More About Shigellosis and Enterotoxigenic Escherichia coli (ETEC) (2012)
A web page that provides general information about shigellosis and ETEC diseases and their current vaccine landscapes.
Page last updated: October 2013.